In March, CGN NEW ENERGY (01811) completed a power generation of 1663.9 gigawatt hours, a year-on-year decrease of 5.7%.
CGN New Energy (01811) announced that in March 2026, the company and its subsidiaries (the Group) completed a total power generation of 1663.9 gigawatt-hours according to the consolidated financial statements, a decrease of 5.7% compared to the same period in 2025. Specifically, wind power projects in China decreased by 33.8%, solar power projects in China increased by 50.4%, hydropower projects in China decreased by 16.0%, and projects in Korea increased by 41.4%.
CGN NEW ENERGY (01811) announced that in March 2026, the company and its subsidiaries (the Group) completed a total power generation of 1663.9 gigawatt-hours, a decrease of 5.7% compared to the same period in 2025. Among these, wind power projects in China decreased by 33.8%, China CECEP Solar Energy projects increased by 50.4%, hydropower projects in China decreased by 16.0%, and projects in Korea increased by 41.4%.
For the three months ending on March 31, 2026, the Group has cumulatively completed a total power generation of 4764.5 gigawatt-hours, a decrease of 0.1% compared to the same period in 2025. Among these, wind power projects in China decreased by 15.2%, China CECEP Solar Energy projects increased by 37.4%, CHINA GAS HOLD projects increased by 1200.0%, hydropower projects in China decreased by 8.7%, and projects in Korea increased by 20.7%.
Related Articles
Sinolink: CoWoS enters a new stage, SIC is expected to enter the period of industrial production volume.
HK Stock Market Move | JUNSHI BIO(01877) rose over 8% in the afternoon. The third largest shareholder did not reduce their holding as planned, and their ownership percentage remains at 5.79%.
HK Stock Market Move | CUTIA-B(02487) surged more than 3%. CU-20101 (injectable type A botulinum toxin) completed Phase III clinical trials in China.
Sinolink: CoWoS enters a new stage, SIC is expected to enter the period of industrial production volume.
HK Stock Market Move | JUNSHI BIO(01877) rose over 8% in the afternoon. The third largest shareholder did not reduce their holding as planned, and their ownership percentage remains at 5.79%.
HK Stock Market Move | CUTIA-B(02487) surged more than 3%. CU-20101 (injectable type A botulinum toxin) completed Phase III clinical trials in China.
RECOMMEND
